Fetuin-A as A Marker of Vascular Calcification in Chronic Kidney Disease
Fetuin-A Marker of Vascular Calcification in Chronic Kidney Disease
DOI:
https://doi.org/10.54393/pjhs.v5i11.2198Keywords:
Chronic Kidney Disease, Human Fetuin A, Vascular Calcifications, AssociationAbstract
Multiple factors contribute to vascular calcification in chronic kidney disease. Fetuin-A is known for its potent inhibitory effects on ectopic calcification Objectives: To determine the association between fetuin-A levels and vascular calcification in chronic kidney disease patients. Methods: 90 samples were collected from patients admitted to the Nephrology ward of Shahida Islam Medical Complex, Lodhran due to renal disease, and 90 samples were collected from normal healthy subjects. Patients with congestive heart failure, use of hormonal contraceptives or hormone replacement therapy, malignancy, pregnancy and with a history of trauma or surgery within a month were excluded. Mann-Whitney was applied to test Serum Fetuin A between cases and controls keeping p<0.05 as statistically significant. Results: Of 90 cases and 90 controls, 63 male (70%) and 27 female (30%) were in cases and 45 (50%) male and female were in the control group. the cases exhibited lower levels of Fetuin-A (0.4416 ± 0.17 g/L) compared to the controls (0.752 ± 0.176 g/L). The clustering revealed a possible association between the severity of chronic kidney disease and decreased Fetuin-A levels. The values ranged from as low as 0.034 to a peak at 2.132 g/L, with several outliers distributed across the chronic kidney disease stage. Conclusions: It was concluded that comparing fetuin-A levels in chronic kidney disease patients to controls revealed a significant correlation. Patients had lower levels of fetuin-A compared to controls.
References
Francis A, Harhay MN, Ong A, Tummalapalli SL, Ortiz A, Fogo AB et al. Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus. Nature Reviews Nephrology. 2024 Apr: 1-3. doi: 10.1038/s41581-024-00820-6. DOI: https://doi.org/10.1038/s41581-024-00820-6
El-Shishtawy S, Sherif N, Ibrahim A, Mamdouh S, Metwaly A, Abd Elazim IM. The Relation Between Fetuin-A and Inflammatory Markers in Cardiovascular Calcification in Hemodialysis Dependent Patient. African Journal of Biological Sciences. 2024 Jan; 20(1): 103-5. doi: 10.21608/AJBS.2024.286311.1089. DOI: https://doi.org/10.21608/AJBS.2024.286311.1089
Werida RH, Abou-Madawy S, Abdelsalam M, Helmy MW. Omega 3 Fatty Acids Effect on the Vascular Calcification Biomarkers Fetuin a and Osteoprotegerin in Hemodialysis Patients. Clinical and Experimental Medicine. 2022 May: 1-0. doi: 10.1007/s10238-021-00740-w. DOI: https://doi.org/10.21203/rs.3.rs-392860/v1
Roca-Tey R, Ramírez de Arellano M, González-Oliva JC, Roda A, Samon R, Ibrik O et al. Is Fetuin-A a Biomarker of Dialysis Access Dysfunction? The Journal of Vascular Access. 2023 May; 24(3): 458-64. doi: 10.1177/11297298211035846. DOI: https://doi.org/10.1177/11297298211035846
Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting Vascular Calcification in Chronic Kidney Disease. Basic to Translational Science. 2020 Apr; 5(4): 398-412. doi: 10.1016/j.jacbts.2020.02.002. DOI: https://doi.org/10.1016/j.jacbts.2020.02.002
Ossareh S, Rayatnia M, Vahedi M, Jafari H, Zebarjadi M. Association of Serum Fetuin-A with Vascular Calcification in Hemodialysis Patients and Its' Impact on 3-year Mortality. Iran Journal of Kidney Disease. 2020 Dec; 14(6): 500-9.
Mohamed ON, Mohamed MR, Hassan IG, Alakkad AF, Othman A, Setouhi A et al. The Relationship of Fetuin-A with Coronary Calcification, Carotid Atherosclerosis, and Mortality Risk in Non-Dialysis Chronic Kidney Disease. Journal of Lipid and Atherosclerosis. 2024 May; 13(2): 194. doi: 10.12997/jla.2024.13.2.194. DOI: https://doi.org/10.12997/jla.2024.13.2.194
Goodman WG. Calcium and Phosphorus Metabolism in Patients Who Have Chronic Kidney Disease. Medical Clinics. 2005 May; 89(3): 631-47. doi: 10.1016/j.mcna.2004.12.005. DOI: https://doi.org/10.1016/j.mcna.2004.12.005
Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D et al. Serum Calcification Propensity And Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. American Journal of Nephrology. 2018 Jul; 48(1): 21-31. doi: 10.1159/000491025. DOI: https://doi.org/10.1159/000491025
Jirak P, Stechemesser L, Moré E, Franzen M, Topf A, Mirna M et al. Clinical Implications of Fetuin-A. Advances in Clinical Chemistry. 2019 Jan; 89: 79-130. doi: 10.1016/bs.acc.2018.12.003. DOI: https://doi.org/10.1016/bs.acc.2018.12.003
Pan X, Wen SW, Bestman PL, Kaminga AC, Acheampong K, Liu A. Fetuin-A in Metabolic Syndrome: A Systematic Review and Meta-Analysis. PloS One. 2020 Mar; 15(3): e0229776. doi: 10.1371/journal.pone.0229776. DOI: https://doi.org/10.1371/journal.pone.0229776
Icer MA and Yıldıran H. Effects of Fetuin-A with Diverse Functions and Multiple Mechanisms on Human Health. Clinical Biochemistry. 2021 Feb; 88: 1-0. doi: 10.1016/j.clinbiochem.2020.11.004. DOI: https://doi.org/10.1016/j.clinbiochem.2020.11.004
Kaur R and Singh R. Mechanistic Insights into CKD-MBD-Related Vascular Calcification and Its Clinical Implications. Life Sciences. 2022 Dec; 311: 121148. doi: 10.1016/j.lfs.2022.121148. DOI: https://doi.org/10.1016/j.lfs.2022.121148
Zununi Vahed S, Mostafavi S, Hosseiniyan Khatibi SM, Shoja MM, Ardalan M. Vascular Calcification: An Important Understanding in Nephrology. Vascular Health and Risk Management. 2020 May; 16: 167-80. doi: 10.2147/VHRM.S242685. DOI: https://doi.org/10.2147/VHRM.S242685
Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M et al. The Structure, Biosynthesis, and Biological Roles of Fetuin-A: A Review. Frontiers in Cell and Developmental Biology. 2022 Jul; 10: 945287. doi: 10.3389/fcell.2022.945287. DOI: https://doi.org/10.3389/fcell.2022.945287
Kashani K, Rosner MH, Ostermann M. Creatinine: From Physiology to Clinical Application. European Journal of Internal Medicine. 2020 Feb; 72: 9-14. doi: 10.1016/j.ejim.2019.10.025. DOI: https://doi.org/10.1016/j.ejim.2019.10.025
Bargnoux AS, Kuster N, Cavalier E, Piéroni L, Souweine JS, Delanaye P et al. Serum Creatinine: Advantages and Pitfalls. Journal of Laboratory and Precision Medicine. 2018 Aug; 3. doi: 10.21037/jlpm.2018.08.01. DOI: https://doi.org/10.21037/jlpm.2018.08.01
Smith ER. The Isolation and Quantitation of Fetuin-A-Containing Calciprotein Particles from Biological Fluids. Kidney Research: Experimental Protocols. 2016: 221-40. doi: 10.1007/978-1-4939-3353-2_15. DOI: https://doi.org/10.1007/978-1-4939-3353-2_15
Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A et al. Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease. Nephron Clinical Practice. 2008 Mar; 108(3): c233-40. doi: 10.1159/000120209. DOI: https://doi.org/10.1159/000120209
Makulska I, Szczepańska M, Drożdż D, Polak-Jonkisz D, Zwolińska D. The Importance of Fetuin-A in Vascular Calcification in Children with Chronic Kidney Disease. Advances in Clinical and Experimental Medicine. 2019; 28(4): 499-505. doi: 10.17219/acem/82517. DOI: https://doi.org/10.17219/acem/82517
Cottone S, Nardi E, Mule G, Vadala A, Lorito MC, Riccobene R et al. Association Between Biomarkers of Inflammation and Left Ventricular Hypertrophy in Moderate Chronic Kidney Disease. Clinical Nephrology. 2007 Apr; 67(4): 209-16. doi: 10.5414/CNP67209. DOI: https://doi.org/10.5414/CNP67209
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
